Accessibility Menu
BrainsWay logo

BrainsWay(NASDAQ) BWAY

Market Cap$574.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+158%
5 Year+276%
1 Year+86%
1 Month+1%
Premium Feature
Moneyball Superscore
86/100
$14.49
+1.33%
+0.19Today
After hours$14.52+$0.03 (+0.21%)
BrainsWay last closing stock price
MetricPriceDate
Last closeUSD 14.302026-08-28
BrainsWay stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.99%USD 14.742026-08-21
1 month+0.99%USD 14.162026-07-29
3 month-10.01%USD 15.892026-05-29
Year to date+50.37%USD 9.512025-12-31
1 year+86.44%USD 7.672025-08-28
3 year+780%USD 1.632023-08-29
5 year+276.32%USD 3.802021-08-27
Since inception+157.89%USD 5.552019-04-17

BrainsWay Financials at a Glance

Market Cap

$574.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$60.99M

Net Income (TTM)

$9.55M

EPS (TTM)

$0.24

P/E Ratio

59.34

Dividend

$0.00

Beta (Volatility)

0.94 (Low)

Price

$14.49

Volume

80,928.172

Open

$14.42

Previous Close

$14.52

Daily Range

$14.19 - $14.67

52-Week Range

$7.14 - $17.40

Estimated Earnings Date

Nov 10, 2026

BWAY News

No articles available.

BWAY: Motley Fool Moneyball Superscore

86

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BrainsWay

BrainsWay Ltd. is a medical device company specializing in non-invasive neurostimulation treatments for mental health disorders. The company is at the forefront of this industry with its Deep Transcranial Magnetic Stimulation (Deep TMS) technology, which targets deeper brain regions than traditional methods.

Products and Services

Deep Transcranial Magnetic Stimulation (Deep TMS) for mental health disorders

Specialized treatments for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD)

Research and development efforts for broader mental health applications

What Makes BrainsWay Ltd. Special

BrainsWay Ltd. distinguishes itself with its proprietary Deep TMS technology, which offers an innovative treatment alternative for patients unresponsive to standard therapies. This technology targets brain areas more effectively, providing a competitive edge in the treatment of depression and OCD.

Five Things You Need to Know

BrainsWay Ltd. focuses on advanced, non-invasive neurostimulation treatments for mental health disorders.

The company has developed a unique Deep TMS technology that sets it apart from traditional treatments.

Leadership in psychiatry and neurotechnology drives the company's research and development efforts.

Strategic collaborations with healthcare providers and research institutions enhance credibility and clinical adoption.

The company aims for geographic expansion and increased market penetration through strategic partnerships and regulatory approvals.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

129

CEO

Hadar Levy, CPA

Website

www.brainsway.com

Headquarters

Jerusalem, JM 9777516, IL

BWAY Financials

Key Financial Metrics (TTM)

Gross Margin

75.33%

Operating Margin

12.18%

Net Income Margin

14.61%

Return on Equity

12.71%

Return on Capital

5.40%

Return on Assets

7.81%

Earnings Yield

1.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$574.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.21M

Volume

80.93K

Avg. Volume

119.71K

Financials (TTM)

Gross Profit

$45.94M

Operating Income

$7.61M

EBITDA

$12.18M

Operating Cash Flow

$8.16M

Capital Expenditure

-$2.47M

Free Cash Flow

$5.69M

Cash & ST Invst.

$62.36M

Total Debt

$7.13M

BrainsWay Performance Analysis

BrainsWay annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 27,070,664-8.8%
20232023-12-31USD 31,703,09617.1%
20242024-12-31USD 41,210,67030.0%
20252025-12-31USD 52,639,30027.7%
BrainsWay sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.0%
Q42025-12-317.6%
Q12026-03-316.8%
Q22026-06-3012.0%
BrainsWay annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.4094.2%
20232023-12-31USD -0.13-68.7%
20242024-12-31USD 0.06N/A
20252025-12-31USD 0.18230.4%
BrainsWay sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-20.0%
Q42025-12-31252.0%
Q12026-03-31-14.8%
Q22026-06-3014.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$17.40M

+37.8%

Gross Profit

$12.99M

+36.7%

Gross Margin

74.62%

N/A

Market Cap

$574.97MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.46M

N/A

Employees

129

N/A

Net Income

$2.76M

+36.0%

EBITDA

$2.88M

-11.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$62.36M

-20.1%

Total Debt

$7.13M

+16.4%

Accounts Receivable

$7.03M

+81.7%

Inventory

$7.31M

+74.5%

Long Term Debt

$5.89M

+12.9%

Short Term Debt

$1.24M

+36.0%

Return on Assets

7.81%

N/A

Return on Invested Capital

8.00%

N/A

Free Cash Flow

$5.46M

-51.3%

Operating Cash Flow

$6.36M

-48.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DCTHDelcath Systems, Inc.
$16.46+0.73%
CERSCerus Corporation
$2.64-0.38%
TCMDTactile Systems Technology, Inc.
$22.98-0.78%
NPCENeuroPace, Inc.
$14.65+1.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About BWAY

What is the current price of BrainsWay?

BrainsWay is trading at $14.52 per share.

What is the 52-week range for BrainsWay?

Over the past 52 weeks, BrainsWay has traded between $7.14 and $17.40.

How much debt does BrainsWay have?

As of the most recent reporting period, BrainsWay reported total debt of $7.13M.

How much cash does BrainsWay have on hand?

BrainsWay reported $62.36M in cash and cash equivalents in its most recent financial results.

What is BrainsWay’s dividend yield?

BrainsWay does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services